Patents Examined by Mark V Stevens
  • Skin moisturizing formulation
    Patent number: 11234924
    Abstract: The present invention discloses an organic skin moisturizer, which extends and improves the skin cells. The composition is dermatologically acceptable and is capable of moisturizing skin for at least twelve hours after topical application to skin even after multiple washings of the skin.
    Type: Grant
    Filed: July 7, 2020
    Date of Patent: February 1, 2022
    Inventor: Tova Palomino
  • Surfactant-free cosmetic composition
    Patent number: 11229586
    Abstract: A surfactant-free cosmetic composition is disclosed. The composition is a stable water in silicone oil (W/S) formulation containing a silicone oil phase portion and an aqueous phase portion, wherein the silicone oil phase portion contains an emollient having a pyrrolidone carboxylic acid group, oil-absorbing powder and silicone oil, and the aqueous phase portion contains 50 wt.% or more of water based on the total weight of the surfactant-free cosmetic composition. The composition may further contain a high content of vitamin C or a vitamin C derivative and has improved long term storage stability.
    Type: Grant
    Filed: June 15, 2020
    Date of Patent: January 25, 2022
    Assignee: AMOREPACIFIC CORPORATION
    Inventors: Seong Chan Eo, Seung Han Park, Byung Fhy Suh, Ji Sik Shin, Dong Won Choi, Byung Guen Chae
  • Arimoclomol formulation
    Patent number: 11229633
    Abstract: The present invention relates to a pharmaceutical formulation which provides for extended release of an active pharmaceutical ingredient selected from N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride, its stereoisomers and the acid addition salts thereof.
    Type: Grant
    Filed: March 23, 2020
    Date of Patent: January 25, 2022
    Assignee: Orphazyme A/S
    Inventors: Anders Mørkeberg Hinsby, Thomas Kirkegaard Jensen, Gert Mads Bolwig, Carlos Roberto Camozzi
  • Opioid receptor modulator dosage formulations
    Patent number: 11229627
    Abstract: Abuse deterrent solid dosage formulations containing 5-({[2-Amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid, and processes for the preparation and administration of these formulations.
    Type: Grant
    Filed: October 21, 2021
    Date of Patent: January 25, 2022
    Assignee: Allergan Holdings Unlimited Company
    Inventors: Tim Costello, Jens Jozef Ceulemans, Eugeen Maria Jozef Jans, Philip Erna H. Heyns
  • Compositions and methods for treating diseases of the nail
    Patent number: 11213519
    Abstract: Methods and compositions for treating disorders of the nail and nail bed. Such compositions contain a vehicle in which all components of the composition are dissolved, suspended, dispersed, or emulsified, a non-volatile solvent, a wetting agent, and a pharmaceutically active ingredient that is soluble in the non-volatile solvent and/or a mixture of the vehicle and the non-volatile solvent, and which composition is effective in treating a disorder of the nail or nail bed.
    Type: Grant
    Filed: December 20, 2019
    Date of Patent: January 4, 2022
    Assignee: BAUSCH HEALTH IRELAND LIMITED
    Inventors: Gareth Winckle, Gregory T. Fieldson
  • Formulation and aerosol canisters, inhalers, and the like containing the formulation
    Patent number: 11207477
    Abstract: Formulations containing pharmaceutical active agent, propellant, and water at least partially adsorbed on or absorbed within one or more nylon pellets or nylon components of, for example, an inhaler such as a metered dose inhaler. Canisters, typically sealed canisters, containing such formulations. Inhalers, such as metered dose inhalers, containing such canisters. Methods of making and using the same.
    Type: Grant
    Filed: May 15, 2018
    Date of Patent: December 28, 2021
    Assignee: Kindeva Drug Delivery L.P.
    Inventor: Peter D. Hodson
  • Immediate release abuse-deterrent granulated dosage forms
    Patent number: 11207318
    Abstract: Described are immediate release oral dosage forms that contain abuse-deterrent features. In particular, the disclosed dosage forms provide deterrence of abuse by ingestion of multiple individual doses. In addition, the disclosed dosage forms provide protection from overdose in the event of accidental or intentional ingestion of multiple individual doses.
    Type: Grant
    Filed: January 23, 2020
    Date of Patent: December 28, 2021
    Assignee: Clexio Biosciences Ltd.
    Inventors: Dinesh K. Haswani, Derek V. Moe, Victoria A. O'Neill, Manuel A. Vega Zepeda
  • Methods for enhanced root nodulation in legumes
    Patent number: 11202450
    Abstract: Disclosed herein are methods of increasing, enhancing, or accelerating root nodulation in a plant, accelerating growth of nitrogen fixing bacteria in nodules of a plant, increasing protein content in a plant, increasing yield of a plant, improving water retention of a plant, or reducing water use of a plant, the method comprising identifying a plant in need of root nodulation, and applying to the plant a composition comprising a protein component comprising yeast stress proteins resulting from subjecting a mixture obtained from the yeast fermentation to stress.
    Type: Grant
    Filed: February 17, 2020
    Date of Patent: December 21, 2021
    Assignee: ADVANCED BIOCATALYTICS CORPORATION
    Inventors: Andrew H. Michalow, Carl W. Podella, John W. Baldridge, Michael G. Goldfeld
  • Preparation method of naltrexone implants
    Patent number: 11197829
    Abstract: The present invention relates to a technical field of pharmaceutical preparation, in particular to a preparation method of naltrexone implants, including the following steps: (1) dissolving naltrexone and polylactic acid in an organic solvent to form naltrexone microspheres, and drying; (2) placing the naltrexone microspheres in a heated tableting mold for tableting, and obtaining naltrexone implant tablets; (3) dissolving the polylactic acid in the organic solvent to obtain a coating solution, and placing the coating solution in a coating pool, and then immersing the naltrexone implant tablets in the coating solution, and drying in a suspended state.
    Type: Grant
    Filed: September 21, 2018
    Date of Patent: December 14, 2021
    Assignee: Shenzhen ScienCare Medical Industries Co. Ltd.
    Inventors: Shugui Yin, Shiqiang Wang, Shaowei Jia, Tao Zhang, Qingzhe Liu
  • Solution and method for reducing the virulence of viruses, bacteria,yeasts, or fungus
    Patent number: 11197824
    Abstract: A method of reducing the virulence of microbes in or on the human body and a method of sanitizing or disinfecting a surface, area, object, or porous or non porous material is provided. The methods comprise applying or injecting a solution having an effective amount of a conjugated diene for substantially reducing the virulence of the microbes or sanitizing or disinfecting a surface, area, object, or porous or non porous material.
    Type: Grant
    Filed: July 24, 2020
    Date of Patent: December 14, 2021
    Inventors: David G. Changaris, Anne L. Carenbauer
  • Compositions and methods for the control of arthropods
    Patent number: 11191268
    Abstract: A composition for the eradication or control of arthropods comprising at least one film-forming compound dispersed in a water continuous phase and at least one wetting agent, wherein the film-forming compound does not comprise silicone. Methods of preparing a composition according to the present invention, uses of the composition and a kit of parts for preparing the composition are also disclosed.
    Type: Grant
    Filed: July 6, 2016
    Date of Patent: December 7, 2021
    Assignee: J.V. Barrett & Co., Limited
    Inventor: Ian Whelan
  • Formulation for oral delivery of proteins, peptides and small molecules with poor permeability
    Patent number: 11185589
    Abstract: The present disclosure is directed to a pharmaceutical formulation intended for oral delivery of synthetic or natural poorly permeable molecules or salts/solvates thereof having a therapeutic activity. The pharmaceutical formulation can include a synthetic or natural poorly permeable molecule or salt or solvate thereof in an amount 0.01-10 wt. % of the total weight of the formulation; a lipophilic phase comprising triglycerides of fatty acids in an amount of 50-80 wt. % of the total weight of the formulation; and at least one lipophilic surfactant comprising partial esters of polyol and fatty acids in an amount of about 10-50 wt. % of the total weight of the formulation.
    Type: Grant
    Filed: April 10, 2020
    Date of Patent: November 30, 2021
    Assignee: R.P. Scherer Technologies, LLC
    Inventors: Vincent Plassat, Benoit Hilbold, Aurélia Galus, Thomas Pointeaux, Julien Meissonnier
  • Anti-microbial polymer compositions, fibers, and yarns
    Patent number: 11185071
    Abstract: The present disclosure relates the polymer compositions, fibers, and yarns having near-permanent antimicrobial activity, and a method of producing the same. In one embodiment, the antimicrobial polymer composition from 50 wt % to 99.9 wt % of a polymer, from 5 wppm to 1000 wppm of zinc, and from 0.005 wt % to 1 wt % of phosphorus, wherein fibers formed from the polymer composition demonstrate a zinc retention rate of greater than 20% when tested in a dye bath test.
    Type: Grant
    Filed: December 18, 2019
    Date of Patent: November 30, 2021
    Assignee: Ascend Performance Materials Operations LLC
    Inventors: Scott E. Osborn, Wai-shing Yung
  • Methods and compositions for selectively inhibiting pathogenic microbes
    Patent number: 11180452
    Abstract: A method of selectively inhibiting pathogenic microbes includes: providing a compound that is functional as a selective antimicrobial having a structure of Formula 1, or derivative thereof, salt thereof, or stereoisomer thereof, or having any chirality at any chiral center, or tautomer, polymorph, solvate, or combination thereof; and contacting a pathogenic microbe with the compound such that the pathogenic microbe is selectively inhibited; wherein: ring A is a cycloalkyl, heterocycloalkyl, aryl, heteroaryl, or polycycle combination thereof; X is S, SO, or SO2; Y is a linker or bond; Z is CH, CR2, or N; Z1 is C or N to form an imidazopyridine; each Z2, Z3, or Z4 is independently CH, CR2, or N; each Z5 or Z6 is C or CH; each R1, R2, R3 and/or R4 is independently a substituent; m is 0, 1, 2, 3, or 4; and n is zero or a positive integer.
    Type: Grant
    Filed: June 17, 2020
    Date of Patent: November 23, 2021
    Assignees: CFD Research Corporation, The Board of Regents of the University of Oklahoma
    Inventors: Anuj Singhal, Robert H. Cichewicz, Lin Du, JianLan You, Hanumantha Rao Paritala, Abigail Grace Edwards
  • Process of using chlorine dioxide for the attenuation and/or treatment of Coronavirus diseases such as COVID-19 and disabling, treating or attenuating the SARS CoV-2 virus, and its future infective variants
    Patent number: 11179415
    Abstract: The use of chlorine dioxide (CLO2) to kill or disable pathogens such as viruses, particularly those of the Coronavirus family. A certain amount of CLO2 is used via different modalities, particularly through one's nose or mouth, as a therapeutic. CLO2 can treat, cure and/or prevent diseases, such as methicillin resistant Staphylococcus aureus (MRSA), fungal infections, the common cold, and more particularly a current disease in the year 2020, known as COVID-19. The invention will not only kill or disable SARS CoV-2, which causes COVID-19, but will also kill or disable the next Coronavirus, SARS CoV-3, once CoV-2 mutates and escapes any vaccine against it.
    Type: Grant
    Filed: December 18, 2020
    Date of Patent: November 23, 2021
    Inventor: George William Madray
  • Transdermal absorption preparation
    Patent number: 11179469
    Abstract: Provided is a transdermal absorption preparation that shows superior skin permeability of a drug and that does not easily cause cold flow. A transdermal absorption preparation having a drug-containing layer containing a drug and a polymer, wherein 50-100 wt % of the polymer in the drug-containing layer is a polymer having a glass transition temperature of 30° C.-200° C., and the drug in the drug-containing layer is in an amorphous state.
    Type: Grant
    Filed: March 26, 2018
    Date of Patent: November 23, 2021
    Assignee: Nitto Denko Corporation
    Inventors: Tomohito Takita, Kaiji Fujiwara, Chie Matsumoto
  • Composition for preparing an anti-tumour agent and a method for preparing an anti-tumour agent on the basis of same
    Patent number: 11166908
    Abstract: The invention relates to pharmacology and to a composition for making an antitumor agent in the form of a solution for injection. The composition contains alloferon at a concentration of 0.05 to 0.1% wt, cis-diamminedichloridoplatinum at a concentration of 0.01 to 0.05% wt, and water. The composition of the present invention features antitumor activity and hypotoxicity. 1 Figure, 3 Tables, 5 examples.
    Type: Grant
    Filed: August 29, 2017
    Date of Patent: November 9, 2021
    Inventor: German Petrovich Bekker
  • Water-in-oil emulsion cosmetic
    Patent number: 11166887
    Abstract: A water-in-oil emulsified cosmetic preparation that, even without substantially comprising a UV scattering agent: exhibits a higher UV protection effect than immediately after application, as a result of coming in contact with moisture, has excellent appearance, usability, and washability. The water-in-oil emulsified cosmetic preparation includes 6%-40% by mass of a UV absorber (A), an oil phase thickener (B), and at least one hydrophobic powder (C) selected from (i)-(iii), namely (i) hydrophobized talc, (ii) silicone powder having an average particle diameter of at least 30 ?m, and (iii) crosslinked polymethyl methacrylate powder having a crosslinking density of at least 40%; and not including a UV scattering agent or containing no more than 6% by mass of same.
    Type: Grant
    Filed: June 6, 2018
    Date of Patent: November 9, 2021
    Assignee: SHISEIDO COMPANY, LTD.
    Inventors: Marianne Ayaka Touati, Satoshi Yamaki, Yurika Watanabe, Takahiro Katori, Yuko Nagare
  • Opioid receptor modulator dosage formulations
    Patent number: 11160792
    Abstract: Abuse deterrent solid dosage formulations containing 5-({[2-Amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid, and processes for the preparation and administration of these formulations.
    Type: Grant
    Filed: March 24, 2021
    Date of Patent: November 2, 2021
    Assignee: Allergan Holdings Unlimited Company
    Inventors: Tim Costello, Jens Jozef Ceulemans, Eugeen Maria Jozef Jans, Philip Erna H. Heyns
  • Method of manufacturing spheroid having uniform size
    Patent number: 11154506
    Abstract: The present invention relates to a method of manufacturing a spheroid using a composition for a liquid bath for dipping a hydrogel droplet and to a spheroid manufactured thereby. The method of manufacturing the spheroid according to the present invention is capable of successfully forming a spheroid having a 3D spherical shape that is difficult to implement on a planar substrate and also of realizing a spheroid having a uniform size, and thus can be effectively used as a technique for obtaining a spheroid having a 3D spherical shape and a uniform size in the field of cell culture.
    Type: Grant
    Filed: May 1, 2020
    Date of Patent: October 26, 2021
    Assignee: Pensees Inc.
    Inventor: Jaeha Shin